ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1469

Characteristics of Adult Patients with Rheumatic Diseases During the COVID-19 Pandemic: Data from an International Patient Survey
Abstract Number: 1071

Characteristics of Anti-Transcription Intermediary Factor 1-gamma Autoantibody Positive Dermatomyositis Patients in Singapore
Abstract Number: 0415

Characteristics of Arthritis in Adult IgA Vasculitis
Abstract Number: 0516

Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Results from the Long-Term Extension of a Randomized Controlled Phase 3 Trial
Abstract Number: 0306

Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 0020

Characteristics of Rheumatology Outpatients with Suspected or Confirmed COVID-19 During the Pandemic in New York City
Abstract Number: 0176

Characterization and Molecular Mechanism Underlying NEMO Deleted Exon 5 Autoinflammatory Syndrome (NDAS)
Abstract Number: 1420

Characterization of ANCA-Associated Vasculitis Among African American Patients
Abstract Number: 0523

Characterization of Antiphospholipid Antibody-Associated Nephropathy: An International Survey of Renal Pathology Society Members
Abstract Number: 1531

Characterization of Cytokine/chemokine Profile in Patient-derived M1/ M2 Macrophages to Identify Biomarkers for Genetically-defined Systemic Autoinflammatory Diseases
Abstract Number: 0473

Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome
Abstract Number: 0533

Characterization of Older Male Patients with a Fragility Fracture
Abstract Number: 0044

Characterization of Racial Disparities in Rheumatoid Arthritis Treatment Choice and Location of Care
Abstract Number: 1355

Characterization of Remission in Patients with Psoriatic Arthritis Treated with Upadacitinib: Post-hoc Analysis from Two Phase 3 Trials
Abstract Number: 0234

Characterization of Serious Infections with Upadacitinib in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].